| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Steven Parkes, Bethany Mantell, Ebenezer Oloyede, Graham Blackma. Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144802. |
patients' experiences of clozapine for treatment-resistant schizophrenia: a systematic review. |
2024-08-15 |
2024-08-17 |
Not clear |
| Steven Parkes, Bethany Mantell, Ebenezer Oloyede, Graham Blackma. Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144802. |
clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia (trs), however, it remains widely under-utilized in clinical practice. |
2024-08-15 |
2024-08-17 |
Not clear |
| Suresh Thapaliya, Eromona Whiskey, Mudasir Firdos. Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia. BMJ case reports. vol 17. issue 8. 2024-08-14. PMID:39142837. |
clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. |
2024-08-14 |
2024-08-17 |
Not clear |
| Lene Bleich, Renate Grohmann, Waldemar Greil, Dominik Dabbert, Andreas Erfurth, Sermin Toto, Johanna Seifer. Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016. Journal of neural transmission (Vienna, Austria : 1996). 2024-08-13. PMID:39136776. |
clozapine is a second-generation antipsychotic drug that offers superior treatment results in patients with schizophrenia but is also associated with significant risks. |
2024-08-13 |
2024-08-16 |
Not clear |
| Marco Solmi, Giovanni Croatto, Arnav Gupta, Nicholas Fabiano, Stanley Wong, Michele Fornaro, Lynne Kolton Schneider, S Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Merete Nordentoft, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Michele De Prisco, Laurent Boyer, Eduard Vieta, Christoph U Correl. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 88. 2024-08-09. PMID:39121717. |
conversely, second generation antipsychotics (sgas) and clozapine were associated with reduced cardio-cerebrovascular-related mortality, in prevalent samples of schizophrenia. |
2024-08-09 |
2024-08-13 |
Not clear |
| Qi He, Peixin Zhu, Xiyan Liu, Chunyue Hu. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophrenia research. vol 271. 2024-08-07. PMID:39111258. |
association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: a systematic review and meta-analysis. |
2024-08-07 |
2024-08-10 |
Not clear |
| Qi He, Peixin Zhu, Xiyan Liu, Chunyue Hu. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophrenia research. vol 271. 2024-08-07. PMID:39111258. |
we aimed to compare the risk of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine and other sgas. |
2024-08-07 |
2024-08-10 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Kohei Kitagawa, Yuji Yada, Masafumi Kodama, Shinichiro Nakajima, Yoshiki Kishi, Norihito Yamada, Hiroyoshi Takeuch. Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: A 1-year retrospective cohort study. Psychopharmacology. 2024-08-06. PMID:39105768. |
impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: a 1-year retrospective cohort study. |
2024-08-06 |
2024-08-08 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Kohei Kitagawa, Yuji Yada, Masafumi Kodama, Shinichiro Nakajima, Yoshiki Kishi, Norihito Yamada, Hiroyoshi Takeuch. Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: A 1-year retrospective cohort study. Psychopharmacology. 2024-08-06. PMID:39105768. |
clozapine, the standard treatment for treatment-resistant schizophrenia (trs), is generally recommended in a multiple-daily dosing regimen. |
2024-08-06 |
2024-08-08 |
Not clear |
| Syed Ali Bokhari, Lubna Lutfi, Muhanad Elnoor, Beenish Mujahid, Abdelaziz Osma. Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature. Cureus. vol 16. issue 7. 2024-08-05. PMID:39100027. |
polypharmacy to clozapine monotherapy in treatment-resistant schizophrenia: a case report and review of the literature. |
2024-08-05 |
2024-08-07 |
Not clear |
| Syed Ali Bokhari, Lubna Lutfi, Muhanad Elnoor, Beenish Mujahid, Abdelaziz Osma. Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature. Cureus. vol 16. issue 7. 2024-08-05. PMID:39100027. |
this case highlights the efficacy of clozapine monotherapy in managing treatment-resistant schizophrenia after years of ineffective polypharmacy treatment. |
2024-08-05 |
2024-08-07 |
Not clear |
| Syed Ali Bokhari, Lubna Lutfi, Muhanad Elnoor, Beenish Mujahid, Abdelaziz Osma. Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature. Cureus. vol 16. issue 7. 2024-08-05. PMID:39100027. |
the importance of clozapine in treating treatment-resistant schizophrenia cannot be understated. |
2024-08-05 |
2024-08-07 |
Not clear |
| Syed Ali Bokhari, Lubna Lutfi, Muhanad Elnoor, Beenish Mujahid, Abdelaziz Osma. Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature. Cureus. vol 16. issue 7. 2024-08-05. PMID:39100027. |
this case report demonstrates the successful management of treatment-resistant schizophrenia with clozapine monotherapy. |
2024-08-05 |
2024-08-07 |
Not clear |
| Alicja Kawalec, Lena Cichoń, Krzysztof Wilczyński, Małgorzata Janas-Kozi. First onset of persistent neutropenia in patient undergoing long-term clozapine treatment after vaccination against COVID-19 and SARS-CoV-2 infection in short interval - a case report. Psychiatria polska. 2024-08-01. PMID:39088695. |
the paper presents the case of a 23-year-old woman diagnosed with early-onset, treatment-resistant schizophrenia who had been undergoing clozapine treatment with satisfying outcome for over 10 years. |
2024-08-01 |
2024-08-05 |
Not clear |
| Jayashri Kulkarni, Adam De Chellis, Heather Gilbert, Emmy Gavrilidis, Eveline Mu, Leila Karimi, Qi L. Clozapine Safety in Pregnancy: A Clinical Study. Schizophrenia bulletin. 2024-07-20. PMID:39031964. |
pregnant women with persistent schizophrenia and related disorders may require ongoing antipsychotic treatment, including clozapine. |
2024-07-20 |
2024-07-24 |
Not clear |
| Rommy Cedeno, Arturo P Jaramillo, Ahmad R Kha. Comparative Effectiveness of Amisulpride and Clozapine in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis. Cureus. vol 16. issue 6. 2024-07-19. PMID:39027775. |
comparative effectiveness of amisulpride and clozapine in the treatment of schizophrenia: a systematic review and meta-analysis. |
2024-07-19 |
2024-07-21 |
Not clear |
| Hans Joachim de Haas, Dan Cohen, Mariken Beatrijs de Koning, Geke van Weringh, Veroljub Petrovic, Lieuwe de Haan, Daan Johannes Touw, Dragana Ignjatovic Risti. Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER). Psychiatry research. vol 339. 2024-07-19. PMID:39029392. |
clozapine remains the only pharmacological treatment option for treatment-resistant schizophrenia. |
2024-07-19 |
2024-07-22 |
Not clear |
| Lizhi Zhang, Yiying Zhou, Yanhong Xie, Yudong Ying, Yan Li, Sen Ye, Zhengchun Wan. Adjunctive clozapine with bright light mitigates cognitive deficits by synaptic plasticity and neurogenesis in sub-chronic MK-801 treated mice. Pharmacology, biochemistry, and behavior. 2024-07-13. PMID:39002805. |
schizophrenia impacts about 1 % of the global population, with clozapine (clz) being a critical treatment for refractory cases despite its limitations in effectiveness and adverse effects. |
2024-07-13 |
2024-07-16 |
mouse |
| Lingyan Qi, Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking. Frontiers in pharmacology. vol 15. 2024-07-08. PMID:38974031. |
this case report investigated the trajectory of clozapine plasma concentrations over time after smoking cessation in a chinese inpatient with schizophrenia. |
2024-07-08 |
2024-07-11 |
Not clear |
| Lingyan Qi, Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking. Frontiers in pharmacology. vol 15. 2024-07-08. PMID:38974031. |
this case report delineates the temporal response of plasma clozapine concentrations and dose-corrected clozapine plasma concentrations in a 33-year-old inpatient with schizophrenia who had a substantial smoking history and ceased smoking abruptly during dose titration. |
2024-07-08 |
2024-07-11 |
Not clear |